Jefferies Highlights 4 Pillars Of Growth For Organovo Holdings

Jefferies analysts recently attended an analyst day thrown by Organovo Holdings Inc ONVO. Aside from management’s emphasis on its proprietary “3D bioprinting” platform, the other takeaway for Jefferies was increased confidence in the company’s lead products and their value proposition.

Related Link: Organovo Is A Company 3D Printing Human Tissue And Its CEO Is Excited About Livers

Here are four “growth pillars” Jefferies made note of:

1. Preclinical Safety: Initial uptake of 3D bioprinted liver tissue has been positive, with five of the top 25 pharma companies using it for preclinical safety work.
2. Publicity: Expanded data, publications in peer-reviewed journals, and the launch of its 3D kidney tissue will be key drivers of accelerating demand.
3. Drug Discovery: In effect, its 3D bioprinted tissues could allow pharma to develop drugs, with Organovo positioned to collect licensing revenues if those drugs are successfully commercialized.
4. Therapeutic Tissues: The prospect of using bioprinted tissues for in-human clinical trials exists, though currently the company is not heavily invested in this.
5. Intellectual Property Monetization: For the first time, Organovo openly discussed monetizing its intellectual property estate through licensing deals. Organovo already licenses more than 25 licenses on its issued patents.

Organovo shares were trading higher late afternoon Friday at $3.80, up just over 2 percent from Thursday's close.